LivaNova (NASDAQ:LIVN) Rating Increased to Outperform at Robert W. Baird

Robert W. Baird upgraded shares of LivaNova (NASDAQ:LIVN) from a neutral rating to an outperform rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports. They currently have $66.00 target price on the stock, up from their previous target price of $55.00.

A number of other research firms have also issued reports on LIVN. Needham & Company LLC boosted their price target on shares of LivaNova from $72.00 to $75.00 and gave the company a buy rating in a report on Wednesday, July 31st. Stifel Nicolaus boosted their target price on shares of LivaNova from $70.00 to $72.00 and gave the company a buy rating in a research note on Thursday, July 25th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Buy and a consensus target price of $70.80.

LivaNova Stock Up 0.3 %

NASDAQ LIVN opened at $51.23 on Tuesday. LivaNova has a 12 month low of $42.75 and a 12 month high of $64.47. The company’s 50 day simple moving average is $48.86 and its 200 day simple moving average is $53.41. The company has a market capitalization of $2.77 billion, a P/E ratio of -85.38 and a beta of 1.00. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.45 and a quick ratio of 2.94.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.15. The business had revenue of $318.60 million during the quarter, compared to analyst estimates of $305.05 million. LivaNova had a positive return on equity of 13.77% and a negative net margin of 1.37%. Equities research analysts expect that LivaNova will post 2.58 earnings per share for the current fiscal year.

Institutional Trading of LivaNova

Several hedge funds and other institutional investors have recently modified their holdings of LIVN. Hexagon Capital Partners LLC increased its position in LivaNova by 117.8% in the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after purchasing an additional 370 shares during the last quarter. Fifth Third Bancorp increased its holdings in LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after buying an additional 332 shares during the last quarter. Lazard Asset Management LLC bought a new position in LivaNova during the first quarter valued at approximately $84,000. Canada Pension Plan Investment Board acquired a new stake in LivaNova in the second quarter valued at approximately $88,000. Finally, Acadian Asset Management LLC bought a new stake in LivaNova in the first quarter worth approximately $94,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.